RNA therapeutics employ various types of RNA, including coding RNA like mRNA, as well as non-coding RNAs like small interfering RNAs (siRNA), antisense oligonucleotides (ASO), aptamers, ribozymes, and CRISPR/Cas endonucleases, to specifically target proteins and DNA. Recent advances in RNA modification and delivery techniques, combined with its remarkable targeting abilities, have positioned RNA-based formulations as promising therapeutic options for a diverse array of disorders.
There are currently four main classes of RNA therapies in clinical trials: mRNA Vaccines, ASO, RNAi (antisense RNA interference oligonucleotides), and Aptamers, each with varying structures and mechanisms of action. From 2018 to 2022, there were over 850 industry-initiated trials globally, with Asia Pacific involved in over a quarter of the trials. Asia Pacific was also the fastest-growing region compared to the rest of the world in RNA therapy trials with a CAGR of 35% compared to the 20% CAGR of the rest of the world.
This white paper provides comprehensive coverage of the ongoing development of RNA therapies, including a detailed analysis of their clinical trial landscape on a global and regional scale for various disease indications. It specifically emphasizes trends in the Asia Pacific region and includes an appendix summarizing a compilation of approved and late-phase RNA therapies across select locations.